SCHEDULE 13G/A: Frazier Life Sciences Funds and Principals Disclose Significant Passive Stake in Maze Therapeutics, Inc.

An amended Schedule 13G filing reveals that Frazier Life Sciences funds and their managing principals collectively hold substantial beneficial ownership in Maze Therapeutics, Inc., with two individuals exceeding the 10% threshold.

Summary

• Frazier Life Sciences Public Fund, L.P. and its related entities (FHMLSP, L.P. and FHMLSP, L.L.C.) collectively beneficially own 3,272,062 shares of Maze Therapeutics, Inc. Common Stock, representing 7.5% of the class.
• Frazier Life Sciences Public Overage Fund, L.P. and its related entities (FHMLSP Overage, L.P. and FHMLSP Overage, L.L.C.) collectively beneficially own 965,503 shares, representing 2.2% of the class.
• Frazier Life Sciences X, L.P. and its related entities (FHMLS X, L.P. and FHMLS X, L.L.C.) collectively beneficially own 73,872 shares, representing 0.2% of the class.
• Frazier Life Sciences XI, L.P. and its related entities (FHMLS XI, L.P. and FHMLS XI, L.L.C.) collectively beneficially own 139,902 shares, representing 0.3% of the class.
• James N. Topper and Patrick J. Heron each report beneficial ownership of 4,451,339 shares, equating to 10.2% of the outstanding Common Stock.
• Albert Cha and James Brush each report beneficial ownership of 4,237,565 shares, equating to 9.7% of the outstanding Common Stock.
• Daniel Estes reports beneficial ownership of 139,902 shares, equating to 0.3% of the outstanding Common Stock.
• The percentages are calculated based on 43,796,057 shares of Common Stock outstanding as of March 25, 2025, as reported in Maze Therapeutics' Annual Report on Form 10-K filed on March 31, 2025.
• The filing is an Amendment No. 2 to a Schedule 13G, indicating an update to previously reported beneficial ownership.

Sentiment

Score: 5

Explanation: The document is a factual disclosure of beneficial ownership and does not contain subjective language or performance metrics that would indicate a positive or negative sentiment.

Future Outlook

NA

Industry Context

This filing is a standard disclosure of beneficial ownership by institutional investors in a publicly traded company, common in the life sciences sector where specialized funds often take significant positions in emerging biotechnology firms.

Stakeholder Impact

• Shareholders: Provides transparency regarding significant institutional ownership, which can influence market perception and trading activity.
• Company Management: Awareness of large, passive institutional holders who may engage with management on strategic matters, though the filing explicitly states no intent to influence control.

Key Dates

Keywords

Maze Therapeutics Inc., Schedule 13G/A, Beneficial Ownership, Frazier Life Sciences, Institutional Investor, Common Stock, SEC Filing, Investment Fund, Biotechnology